Modulating the renin-angiotensin system by eprosartan or xanthenone drives microglial M2 polarization in a rat model of Parkinson’s disease via regulating the interplay between MKP-1/ miR-155 /SOCS1 and PP2A signaling network
Date
2025-05-28
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Elsevier B.V
Series Info
International Immunopharmacology ; Volume 159 , 26 June 2025 , Article number 114950
Scientific Journal Rankings
Abstract
Despite growing evidence for the renin-angiotensin system (RAS) involvement in Parkinson’s disease (PD), its
role in microglial polarization during disease progression remains unclear. This study explored the ability of
modulating RAS using eprosartan, an AT1R antagonist, and xanthenone, an ACE2 activator, to support microglial
M2 polarization in rats with PD highlighting the roles of miR-155, protein phosphatase 2 A (PP2A), and mitogenactivated protein kinase phosphatase 1 (MKP-1). Rotenone (1.5 mg/kg) was administered to Wistar rats to induce
PD, with concurrent treatments of eprosartan (60 mg/kg/day) or xanthenone (2 mg/kg/day) for 28 days. Both
agents improved motor function and neuronal damage, as evidenced by behavioral, histopathological, and
immunohistochemical analyses. Eprosartan and xanthenone enhanced tyrosine hydroxylase activity and reduced
α-synuclein accumulation in the substantia nigra. Eprosartan and xanthenone modulated the RAS axis by
reducing angiotensin II level and increasing ACE2 activity and Ang 1–7 concentration in the striatum. Importantly, these agents induced a shift in microglial polarization from the M1 proinflammatory phenotype (marked
by reduced IL-1β, iNOS, and CD86) to the M2 anti-inflammatory phenotype (marked by enhanced arginase1,
Ym1, Fizz1 and CD163). This shift was associated with altered STAT signaling pathways, including decreased pSTAT1 and increased p-STAT6. Additionally, levels of miR-155 were decreased, and levels of SOCS1, MKP-1, and
PP2A were increased. These findings address a critical gap in understanding how RAS modulation can influence
neuroinflammation through microglial polarization via regulating the interplay between MKP-1/ miR-155
/SOCS1 and PP2A, offering a promising therapeutic strategy to mitigate neurodegeneration and inflammation in
PD.
Description
SJR 2024
1.239 Q1
H-Index
155
Keywords
Eprosartan, Microglial polarization, Parkinson's disease, RAS axis, Xanthenone
Citation
Alhadad, M. A., Zaafan, M. A., El-Tanbouly, D. M., Elbrairy, A. I., & Zaki, H. F. (2025). Modulating the renin-angiotensin system by eprosartan or xanthenone drives microglial M2 polarization in a rat model of Parkinson’s disease via regulating the interplay between MKP-1/ miR-155 /SOCS1 and PP2A signaling network. International Immunopharmacology, 159, 114950. https://doi.org/10.1016/j.intimp.2025.114950